| __timestamp | ACADIA Pharmaceuticals Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 60602000 | 3004000 |
| Thursday, January 1, 2015 | 76369000 | 26972000 |
| Friday, January 1, 2016 | 4406000 | 58187000 |
| Sunday, January 1, 2017 | 13060000 | 79479000 |
| Monday, January 1, 2018 | 18330000 | 94123000 |
| Tuesday, January 1, 2019 | 19598000 | 114249000 |
| Wednesday, January 1, 2020 | 20550000 | 131328000 |
| Friday, January 1, 2021 | 19141000 | 150991000 |
| Saturday, January 1, 2022 | 10166000 | 206997000 |
| Sunday, January 1, 2023 | 45731000 | 255000000 |
| Monday, January 1, 2024 | 312068000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Incyte Corporation and ACADIA Pharmaceuticals Inc. from 2014 to 2023. Over this period, Incyte Corporation has consistently outpaced ACADIA Pharmaceuticals in terms of cost of revenue, with a notable increase of approximately 8,400% from 2014 to 2023. In contrast, ACADIA Pharmaceuticals experienced a more modest growth of around 24% during the same period.
Incyte's cost of revenue peaked in 2023, reaching a staggering 255 million, while ACADIA's highest was in 2015 at 76 million. This disparity highlights Incyte's aggressive expansion and investment in revenue-generating activities. As the pharmaceutical landscape continues to shift, these insights provide a window into the strategic priorities of these two industry players.
Analyzing Cost of Revenue: Sanofi and Incyte Corporation
Cost of Revenue Comparison: Gilead Sciences, Inc. vs ACADIA Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Incyte Corporation and Grifols, S.A.
Incyte Corporation vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Incyte Corporation vs Supernus Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Mesoblast Limited
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Incyte Corporation and MiMedx Group, Inc.'s Expenses
Cost Insights: Breaking Down Dr. Reddy's Laboratories Limited and ACADIA Pharmaceuticals Inc.'s Expenses
Cost of Revenue: Key Insights for Exelixis, Inc. and ACADIA Pharmaceuticals Inc.
Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Telix Pharmaceuticals Limited vs ACADIA Pharmaceuticals Inc.